Prothrombin Time (PT with INR)
Liver0 parametersReport in 4HrsAt Home
No Fasting Required
Details
Prothrombin Time (PT) measures the time it takes for blood plasma to clot after the addition of tissue factor (thromboplastin)
₹149₹450
67% OFF
FREE:AI Insights
Prothrombin Time (PT with INR) - Comprehensive Medical Test Guide
- Why is it done?
- Measures the time it takes for blood to clot after tissue factor and calcium are added to plasma
- Evaluates the extrinsic pathway of blood coagulation (factors I, II, V, VII, and X)
- Primary reasons for ordering:
- Monitoring anticoagulation therapy, especially warfarin (Coumadin) treatment
- Assessing bleeding risk before surgical procedures
- Evaluating unexplained bleeding or bruising
- Investigating liver disease (since liver produces clotting factors)
- Screening for clotting disorders as part of routine preoperative evaluation
- Monitoring patients with atrial fibrillation, thromboembolism, or mechanical heart valves
- Typical timing and circumstances:
- Performed during baseline assessment before starting warfarin therapy
- Regularly monitored (usually every 2-4 weeks initially, then monthly to every 12 weeks for stable patients on warfarin)
- Performed within 7-10 days before planned surgery
- Ordered when patients present with signs of bleeding disorders
- Normal Range
- Normal PT range:
- 11.0 to 13.5 seconds (may vary slightly between laboratories depending on reagents and methods used)
- Normal INR (International Normalized Ratio) range:
- 0.8 to 1.1 (or 1.0 to 1.2, depending on laboratory standards)
- Units of measurement:
- PT is measured in seconds (sec)
- INR is a dimensionless ratio (unitless)
- Interpretation of results:
- Normal (negative result): PT within normal range and INR 0.8-1.1 indicates adequate clotting function and normal bleeding risk
- Prolonged PT (High/Abnormal): PT exceeding upper normal limit indicates delayed clotting, increased bleeding risk, or poor warfarin tolerance
- Elevated INR (on warfarin therapy): Therapeutic INR ranges depend on indication (typically 2.0-3.0 for most conditions, 2.5-3.5 for mechanical heart valves); higher values increase bleeding risk
- Shortened PT (Low/Abnormal): PT less than normal range may indicate thrombosis risk or decreased anticoagulation effect
- Borderline values: Results near upper or lower limits require clinical correlation and may necessitate repeat testing
- What normal vs abnormal means:
- Normal: Blood coagulation system is functioning properly; safe to proceed with elective surgery; adequate clotting factors are present
- Abnormal (prolonged): Increased bleeding risk; coagulation cascade is impaired; warfarin dose may need adjustment; may indicate liver disease, vitamin K deficiency, or clotting factor deficiency
- Normal PT range:
- Interpretation
- Detailed result interpretation:
- PT 11-13.5 seconds, INR 0.8-1.1: Normal clotting function; no bleeding disorder; adequate for surgery
- PT >13.5 seconds (mildly prolonged): INR 1.2-2.0 suggests possible vitamin K deficiency, mild liver disease, or early anticoagulation effect
- PT significantly prolonged (>18 seconds): INR >3.0-4.0 indicates significant prolongation, increased bleeding risk; warfarin overdose possible; investigation into underlying cause necessary
- PT severely prolonged (>25 seconds): INR >5.0 represents critical prolongation with high bleeding risk; intervention likely necessary
- PT shorter than expected in patient on warfarin: May indicate inadequate anticoagulation; drug interaction; poor compliance; INR <therapeutic range increases thrombosis risk
- Clinical significance of different patterns:
- Progressive prolongation: Suggests worsening liver disease or additional vitamin K deficiency
- Sudden prolongation in stable patient: Suggests new medication interaction, poor compliance, dietary change, or acute illness
- Discordance between PT and aPTT: If PT prolonged but aPTT normal, suggests factor VII deficiency or liver disease; if both prolonged, suggests disseminated intravascular coagulation or severe liver disease
- Factors that may affect readings:
- Medications: Warfarin (prolongs), aspirin, NSAIDs, antibiotics, corticosteroids, certain herbal supplements (garlic, ginkgo)
- Diet: Vitamin K-rich foods (leafy greens) can reduce warfarin effect; alcohol consumption increases warfarin effect
- Liver function: Liver disease prolongs PT (produces clotting factors)
- Vitamin K status: Deficiency prolongs PT; supplementation shortens it
- Pregnancy: Can shorten PT due to increased clotting factors
- Laboratory factors: Different reagents, testing method, and sample collection can affect results; time delay before processing can prolong results
- Detailed result interpretation:
- Associated Organs
- Primary organ systems involved:
- Hepatic system (Liver): Produces clotting factors I, II, V, VII, IX, X; liver disease directly affects PT
- Hematologic system: Evaluates blood clotting cascade and coagulation factors
- Gastrointestinal system: Involved in vitamin K absorption (necessary for factor production)
- Medical conditions commonly associated with abnormal results:
- Liver disease: Cirrhosis, hepatitis, alcoholic liver disease (prolongs PT significantly)
- Vitamin K deficiency: Malabsorption, antibiotic use, dietary insufficiency
- Disseminated intravascular coagulation (DIC): Severe illness, sepsis, malignancy
- Clotting factor deficiencies: Factor II, V, VII, or X deficiency (rare congenital or acquired)
- Fibrinogen disorders: Afibrinogenemia, dysfibrinogenemia
- Malabsorption syndromes: Celiac disease, cystic fibrosis, inflammatory bowel disease
- Diseases this test helps diagnose or monitor:
- Anticoagulation effectiveness: Monitors warfarin therapy in conditions like atrial fibrillation, thromboembolism, mechanical heart valves
- Bleeding disorders: Hemophilia A (some cases), factor deficiencies
- Liver disease: Primary biliary cirrhosis, primary sclerosing cholangitis, viral hepatitis
- Nutritional disorders: Vitamin K malabsorption
- Potential complications or risks associated with abnormal results:
- Prolonged PT: Increased risk of bleeding including spontaneous bleeding, intracranial hemorrhage, gastrointestinal bleeding, bleeding after minor trauma
- Shortened PT/INR <therapeutic: Risk of thrombosis, stroke, pulmonary embolism, valve thrombosis (in mechanical valves)
- Operating room complications: If PT significantly prolonged, surgery may be delayed or cancelled; increased intraoperative and postoperative bleeding risk
- Primary organ systems involved:
- Follow-up Tests
- Additional tests recommended based on abnormal PT results:
- Activated Partial Thromboplastin Time (aPTT): Evaluates intrinsic and common pathways; helps differentiate cause of prolonged PT
- Bleeding Time or PFA-100: Evaluates platelet function if thrombocytopenia suspected
- Fibrinogen level: Determines if low fibrinogen is cause of prolonged PT
- Thrombin Time (TT): Measures final step of coagulation cascade
- Individual Factor Assays: If PT/aPTT abnormalities suggest specific factor deficiency (factors II, V, VII, X for PT pathway)
- Further investigations based on clinical context:
- Liver Function Tests: If liver disease suspected (ALT, AST, bilirubin, albumin)
- Vitamin K level: If vitamin K deficiency suspected
- Platelet Count: To evaluate thrombocytopenia contributing to bleeding
- D-dimer and Fibrin Degradation Products: If DIC suspected
- Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP) may be administered if life-threatening bleeding occurs
- Monitoring frequency for ongoing conditions:
- Warfarin therapy initiation: PT/INR checked every 2-3 days until stable
- Warfarin dose adjustment phase: Weekly or biweekly testing until INR stable
- Stable warfarin patients: Every 4 weeks to every 12 weeks (monthly to every 3 months); frequency depends on patient stability and institutional protocols
- After medication changes or illness: Testing may be needed within 1-2 weeks to assess impact on anticoagulation
- Related tests providing complementary information:
- Complete Blood Count (CBC): Evaluates hemoglobin for anemia (bleeding consequence) and platelet count
- Comprehensive Metabolic Panel (CMP): Assesses kidney and liver function affecting coagulation
- Bleeding Time (now rarely used): Was used to assess platelet plug formation
- Additional tests recommended based on abnormal PT results:
- Fasting Required?
- Fasting requirement: NO
- Fasting is not required for PT/INR testing
- Food and drink do not affect PT/INR results
- Test can be performed at any time of day
- Medications to avoid:
- Do NOT discontinue warfarin before testing (unless specifically instructed by physician)
- Do NOT start taking aspirin or NSAIDs without consulting physician if on anticoagulation
- Inform healthcare provider of all medications and supplements being taken
- Other patient preparation requirements:
- Standard blood draw preparation: Arrive on time for scheduled appointment
- Wear loose, comfortable clothing to facilitate blood draw from arm
- Relax for 5 minutes before blood draw to obtain accurate baseline results
- Maintain consistent diet: For warfarin patients, keep vitamin K intake consistent (avoid sudden increases or decreases in leafy green vegetables)
- Limit alcohol consumption: Alcohol affects warfarin metabolism and can alter PT/INR
- Sample collection timing: For most patients, test can be done at convenient time; for comparison, try to maintain consistent testing time
- Bring insurance card and identification to appointment
How our test process works!
